Respiratory Syncytial Virus (RSV) Diagnostics Market Prophesied to Grow at a Faster Pace

30/dic/2020 07:49:50 Grand View Research Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Respiratory Syncytial Virus (RSV) diagnostics market is expected to reach USD 1.2 billion by 2022, according to a new study by Grand View Research Inc. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected to be vital impact rendering drivers for RSV diagnostics market.

According to the statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due to RSV infections. This is anticipated to trigger demand for testing of these conditions over the forecast period.

Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted to increase the infant population substantially over the next seven years. According to the statistics, it is estimated that about 134.2 million births took place in 2014, which are prone to RSV infections and require diagnosis, thus forming a large market base.

In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt to promote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.

Browse Details of Report @


Further key findings from the study suggest:

·         Chromatographic immunoassay technology based products are expected to witness the fastest growth at a CAGR above 10.0% over the next seven years owing to their higher specificity than molecular diagnostic products. The commercially available test kits include Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.

·         Hospitals are predicted to dominate the RSV diagnostics market followed by home care. Together, they are expected to contribute over 50.0% of the market share in 2022. Increasing demand for home care diagnostic devices by patients is anticipated to drive growth of the segment over the next seven years.

·         North America is anticipated to dominate the market and contribute a revenue share of over 40.0% by 2022. Rising awareness among the population base and favorable initiatives by the government agencies such as the WHO, PAHO, and WSAID to initiate and implement newborn screening are expected to drive growth.

·         Key players of the market include Alere Inc., EMD Millipore, BD and Company, Ortho Clinical Diagnostics, Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific Inc. CLIA waiver and launch of RSV assays by companies like Roche Diagnostics, Becton Dickinson and Company, and Alere Inc. are expected to boost market growth over the forecast period.

Grand View Research has segmented the Global Respiratory Syncytial Virus diagnostics market on the basis of products, end-use, and region:

RSV Diagnostics Market Product Outlook (Revenue, USD Million, 2012 - 2022)

·         Direct Fluorescence Antibody (DFA) Method

·         Rapid Antigen Diagnostic Tests (RADTs)

·         Molecular Diagnostics

·         Chromatographic Immunoassay

·         Diagnostic Imaging

·         Gel Microdroplets

·         Flow Cytometry

·         Others

RSV Diagnostics Market End-use Outlook (Revenue, USD Million, 2012 - 2022)

·         Hospitals

·         Laboratory

·         Clinics

·         Homecare

blog comments powered by Disqus è un servizio offerto da Factotum Srl